U.S. markets closed

Moderna, Inc. (MRNA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
218.85+1.85 (+0.85%)
At close: 4:00PM EDT

Moderna, Inc.

200 Technology Square
Cambridge, MA 02139
United States
617 714 6500
http://www.modernatx.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees1,300

Key Executives

NameTitlePayExercisedYear Born
Dr. Noubar B. Afeyan Ph.D.Co-Founder, Independent Non Exec. Chairman & Member of Technology Advisory Board107.5kN/A1963
Mr. Stephane BancelCEO & Director3.86MN/A1973
Dr. Stephen HogePres1.26M19.56M1976
Mr. David W. MelineCFO & Principal Accounting Officer932.62kN/A1957
Dr. Tal ZaksChief Medical Officer1.25M67.49M1966
Mr. Juan AndresChief Technical Operations & Quality Officer1.25M9.32M1965
Dr. John V. W. ReyndersChief Information OfficerN/AN/AN/A
Dr. Melissa J. MooreChief Scientific Officer & Member of Scientific Advisory BoardN/AN/AN/A
Ms. Lavina Talukdar CFASr. VP & Head of Investor RelationsN/AN/AN/A
Ms. Shannon Thyme KlingerChief Legal Officer & Corp. Sec.N/AN/A1971
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Corporate Governance

Moderna, Inc.’s ISS Governance QualityScore as of June 1, 2021 is 7. The pillar scores are Audit: 3; Board: 7; Shareholder Rights: 8; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.